---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042786"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:20:23.951367+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma doses first three patients in Phase 2 trial of Ropidoxuridine for glioblastoma

## Summary
- First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma.
- Trial targets IDH wild-type, methylation-negative glioblastoma patients with no cure.
- Initial 40 patients randomized to 1,200 mg/day or 960 mg/day; then add 14 on optimal dose.
- Expected trial completion in 18-24 months.
- Orphan Drug Designation from FDA provides potential 7-year exclusivity if approved.

## SEC filing metadata
- accession: 0001493152-24-042786
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224042786/0001493152-24-042786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224042786/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042786
- JSON: https://secwatch.observer/filing/0001493152-24-042786.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.